All

Jazz Pharmaceuticals to Present Xywav Narcolepsy Data at 2026 AAN Annual Meeting

New poster presentation will detail self-reported outcomes in patients with narcolepsy treated with high dosages of low-sodium oxybate in the DUET study.

All

The Once-Nightly, Salt-Free, Artificial Sweetener-Free Oxybate in the Works for Narcolepsy, IH

Avadel Pharmaceuticals has licensed valiloxybate from XWPharma Ltd.

All

FDA Approves Once-Nightly Treatment for Narcolepsy

The approval of the extended-release formulation of sodium oxybate allows for uninterrupted sleep and full treatment benefits in a single bedtime dose for people with narcolepsy.

Jazz Hits Record Q3 Revenue with Strong Growth in Sleep Portfolio

Nov 6, 2024 | Pharmaceuticals

Jazz Pharmaceuticals reported record third-quarter 2024 revenues of over $1.05 billion, with strong performance from its sleep portfolio.

Jazz Presents New Phase 4 Data on Xywav’s Impact on Narcolepsy and IH

Nov 1, 2024 | Pharmaceuticals

Top-line results show improvements on excessive daytime sleepiness and key polysomnography outcomes.

Court Denies Jazz’s Challenge of Avadel’s Orphan Drug Lumryz

Nov 1, 2024 | Prescription Drugs

A US court ruling supports the FDA’s approval of the once-nightly narcolepsy drug Lumryz, following a lawsuit by Jazz Pharmaceuticals challenging the drug’s orphan status and clinical superiority.

Narcolepsy Patients Prefer Once-Nightly Lumryz Over Twice-Nightly Oxybate

Sep 3, 2024 | Pharmaceuticals

Survey data demonstrate that 94% of people with narcolepsy prefer the once-nightly regimen of Lumryz over twice-nightly oxybate regimens.

Narcolepsy Medication Lumryz Linked to Weight Loss

Aug 20, 2024 | Weight

Nearly one in five study participants treated with the extended-release sodium oxybate medication experienced clinically meaningful weight loss.

Xywav Helps Propel Jazz to Over $1 Billion in Q2 Revenues

Aug 2, 2024 | Pharmaceuticals

Jazz reports second-quarter earnings, with growth driven in part by a 13% increase in Xywav sales.

Narcolepsy, Idiopathic Hypersomnia Study Reinforces Importance of Individualized Oxybates Dosing

Jul 19, 2024 | Hypersomnias, Prescription Drugs

Researchers analyze Xywav and Xyrem’s population pharmacokinetic and exposure-responses, shining light on the dosing and titration of oxybates.

Narcolepsy Significantly Increases Risk of Cardiovascular Disease

Jun 4, 2024 | Heart, Narcolepsy

Two new studies reveal that narcolepsy is an independent risk factor for cardiovascular disease and adverse cardiac events.

Jazz Announces New Xywav Studies Among 13 Sleep Medicine Abstracts at SLEEP 2024

May 31, 2024 | Pharmaceuticals

Research includes phase 4 study design of low-sodium oxybate, Xywav efficacy in narcolepsy with psychiatric and neurologic comorbidities, and assessments of idiopathic hypersomnia burden.

Avadel to Present New Data on Lumryz for Narcolepsy at SLEEP 2024

May 22, 2024 | Narcolepsy

Avadel will present a series of new analyses highlighting the efficacy, safety, and patient preference for Lumryz, a once-nightly, extended-release formulation of sodium oxybate.

Jazz to Highlight Narcolepsy and IH Research at AAN 2024

Apr 11, 2024 | Idiopathic Hypersomnia, Narcolepsy

The research includes an oral presentation revealing that individuals with idiopathic hypersomnia experienced higher odds of comorbid conditions, such as cardiovascular disease.

Jazz and Avadel Both Secure Wins in Patent Lawsuit Over Narcolepsy Drug

Mar 5, 2024 | Narcolepsy

A jury from the United States District Court for the District of Delaware delivered a mixed verdict in a patent lawsuit between Jazz Pharmaceuticals Inc and Avadel Pharmaceuticals plc concerning Avadel’s narcolepsy medication Lumryz.

How to Select the Most Suitable Pharmacotherapy for Type 1 Narcolepsy Patients

Jan 26, 2024 | Narcolepsy, Prescription Drugs

Sleep specialists share practical tips on choosing medications that treat narcolepsy symptoms, including excessive daytime sleepiness and cataplexy.

Jazz Highlights Continued Need for Low-Sodium Treatment Option for Narcolepsy and IH

Oct 23, 2023 | Heart, Idiopathic Hypersomnia, Narcolepsy, Pharmaceuticals

Jazz Pharmaceuticals announced new data highlighting the importance of low-sodium treatment options to help manage cardiovascular risk in patients with narcolepsy and idiopathic hypersomnia.